Shifa Biomedical

Executive Summary

Shifa Biomedical Corporation is a privately held, preclinical-stage biopharmaceutical company dedicated to developing cost-effective small molecule drugs for cardiovascular disease. Based in Malvern, Pennsylvania, and founded in 2006, the company leverages expertise in molecular biology, biochemistry, and computational chemistry to target novel pathways. Its lead program is an oral, small molecule inhibitor of PCSK9 designed to lower LDL cholesterol, a validated target for managing hypercholesterolemia and reducing cardiovascular risk. By focusing on an oral formulation, Shifa aims to offer a more convenient and potentially cheaper alternative to existing injectable PCSK9 inhibitors (e.g., Repatha, Praluent), which could significantly enhance patient adherence and market reach. The company is currently in preclinical development and has not yet disclosed specific funding rounds or partnerships, but its approach addresses a large unmet need in the cardiovascular space, given that statins remain insufficient for many patients and injectable therapies are underutilized due to cost and compliance issues.

Upcoming Catalysts (preview)

• Q4 2026IND-enabling studies completion and regulatory submission35% success
• Q3 2026Presentation of preclinical proof-of-concept data at a major cardiology conference50% success
• Q2 2026Potential Series A or B financing round to advance the lead program40% success